← back to search

Daohan Yu

Harbin Medical University · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research focused on Temozolomide and Glioma, with related work in PKM2, Histone, Gene knockdown. Notable publications include 'Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR–Cas gene editing', 'Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway', and 'LncRNA‐Mediated TPI1 and PKM2 Promote Self‐Renewal and Chemoresistance in GBM'.
h-index
citations
221
works
9
NIH funding
primary concept
email

Recent publications

From pathology to therapy: A comprehensive review of ATRX mutation related molecular functions and disorders
Mutation Research/Reviews in Mutation Research 2025cited by 3position: middledoi
Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR–Cas gene editing
Nature Nanotechnology 2024cited by 96position: middledoi
LncRNA‐Mediated TPI1 and PKM2 Promote Self‐Renewal and Chemoresistance in GBM
Advanced Science 2024cited by 16position: middledoi
A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance
Neuro-Oncology 2024cited by 7position: middledoi
Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway
Cancer Letters 2023cited by 71position: middledoi
HK3 stimulates immune cell infiltration to promote glioma deterioration
Cancer Cell International 2023cited by 13position: middledoi
Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma
Cancer Cell International 2023cited by 7position: middledoi
Development and validation of a pyroptosis-related genes signature for risk stratification in gliomas
Frontiers in Genetics 2023cited by 6position: middledoi
LncRNA-mediated TPI1 and PKM2 promote self-renewal and chemoresistance in GBM
Research Square 2023cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Junzhe Zhong · Harbin Medical University8 papers (2023–2024)Jinquan Cai · Harbin Medical University7 papers (2023–2024)Dan Song · Harbin Medical University7 papers (2023–2024)Yuxiang Liu · Harbin Medical University6 papers (2023–2024)Yu Song · Harbin Medical University6 papers (2023–2024)Penggang Sun · Harbin Medical University6 papers (2023–2024)Chuanlu Jiang · Fudan University6 papers (2023–2025)Kaifu Tian · Harbin Medical University6 papers (2023–2024)Tianye Xu · Harbin Medical University6 papers (2023–2024)Xiangqi Meng · Sun Yat-sen University5 papers (2023–2024)Wenbin Ma · Nanjing University of Aeronautics and Astronautics4 papers (2023–2024)Xiangqi Meng · Kunming University of Science and Technology4 papers (2023–2025)Hanwen Xuan · Harbin Medical University4 papers (2023–2024)Xinyu Wang · Wannan Medical College3 papers (2023–2024)Ziwei Li · Guiyang Medical University3 papers (2023–2023)Changxiao Yang · Harbin Medical University3 papers (2023–2024)Ruofei Shen · Harbin Medical University3 papers (2023–2024)Xinyu Wang · Tongji University2 papers (2023–2023)Hao Chen · Shandong University2 papers (2023–2024)Hao Chen · Hebei Medical University2 papers (2023–2024)